Internal Medicine papers
Pofolia’s corpus holds 60 papers from Internal Medicine (2012–2021), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, 4,820 citations).
- The 20 papers listed have 34,705 citations between them.
- 18 of the 20 with a known journal quartile appeared in a Q1 journal.
- 15 have a free full text (open access).
- Most frequent journals: New England Journal of Medicine, Journal of Clinical Oncology, Circulation.
- Published between 2012 and 2020.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
European Heart Journal · 2019 · Q1 · SJR 5.00 · FWCI 344.02 · 4,820 citations · Open access
These guidelines provide updated evidence-based strategies for diagnosing and managing acute pulmonary embolism (PE), aiming to assist healthcare professionals in daily practice.
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
European Heart Journal · 2014 · Q1 · SJR 5.00 · FWCI 253.12 · 3,148 citations · Open access
These guidelines represent the European Society of Cardiology's (ESC) consensus on diagnosing and managing acute pulmonary embolism, based on the scientific and medical knowledge available in 2014.
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
New England Journal of Medicine · 2012 · Q1 · SJR 18.00 · FWCI 152.95 · 2,353 citations · Open access
A fixed-dose oral rivaroxaban regimen proved noninferior to standard anticoagulant therapy for treating symptomatic pulmonary embolism, with a significantly lower rate of major bleeding.
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 163.85 · 2,294 citations · Open access
A fixed-dose oral regimen of apixaban was noninferior to conventional therapy for treating acute venous thromboembolism, significantly reducing bleeding events.
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 140.59 · 1,869 citations
Once-daily edoxaban, an oral factor Xa inhibitor, proved non-inferior to warfarin for treating venous thromboembolism and significantly reduced bleeding events.
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
The Journal of Experimental Medicine · 2012 · Q1 · SJR 5.00 · FWCI 59.59 · 1,807 citations · Open access
Researchers developed a novel mouse model of deep vein thrombosis (DVT) and found that monocytes and neutrophils initiate the condition by activating coagulation, while neutrophils and platelets propagate it through NETs and leukocyte recruitment, respectively.
Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism
New England Journal of Medicine · 2014 · Q1 · SJR 18.00 · FWCI 94.58 · 1,652 citations · Open access
In intermediate-risk pulmonary embolism patients, tenecteplase plus heparin significantly reduced death or hemodynamic decompensation by 7 days (2.6% vs. 5.6%) compared to placebo, but increased major hemorrhage and stroke risk.
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
European Respiratory Journal · 2019 · Q1 · SJR 5.00 · FWCI 157.75 · 1,622 citations · Open access
This document presents the 2019 European Society of Cardiology (ESC) Guidelines for the diagnosis and management of acute pulmonary embolism (PE), developed in collaboration with the European Respiratory Society (ERS).
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
New England Journal of Medicine · 2017 · Q1 · SJR 18.00 · FWCI 163.34 · 1,611 citations
Oral edoxaban proved noninferior to standard low-molecular-weight heparin (dalteparin) for preventing recurrent venous thromboembolism (VTE) or major bleeding in cancer patients.
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Journal of Clinical Oncology · 2019 · Q1 · SJR 4.00 · FWCI 144.97 · 1,485 citations · Open access
Updated ASCO guidelines recommend offering thromboprophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk cancer outpatients, and add rivaroxaban and edoxaban as options for VTE treatment.
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Blood Advances · 2020 · Q1 · SJR 3.00 · FWCI 85.40 · 1,434 citations · Open access
The American Society of Hematology (ASH) will continue to monitor evidence for its 2020 Venous Thromboembolism (VTE) management guidelines, opting against revision or retirement at this time.
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
Journal of Clinical Oncology · 2015 · Q1 · SJR 4.00 · FWCI 200.62 · 1,374 citations
The 2014 ASCO guideline update confirms existing recommendations for venous thromboembolism (VTE) prophylaxis and treatment in cancer patients, finding no new evidence to warrant changes from the 2013 guidelines.
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Journal of Clinical Oncology · 2018 · Q1 · SJR 4.00 · FWCI 150.56 · 1,330 citations
In cancer patients with venous thromboembolism (VTE), the oral factor Xa inhibitor rivaroxaban significantly reduced VTE recurrence by 57% over 6 months compared to standard low molecular weight heparin (dalteparin).
Epidemiology of cancer-associated venous thrombosis
Blood · 2013 · Q1 · SJR 5.00 · FWCI 35.59 · 1,202 citations · Open access
Cancer-associated venous thrombosis is common but its incidence varies widely due to differences in patient populations, follow-up methods, and cancer types/stages. Patients with this condition generally have poorer outcomes and higher mortality.
The Role of CT Pulmonary Angiography in the Investigation of Unilateral Pleural Effusions
Respiration · 2013 · Q2 · FWCI 64.89 · 1,187 citations · Open access
CT pulmonary angiography (CTPA) combined with pleural-phase thoracic CT is recommended for investigating unilateral pleural effusions, as pulmonary embolism (PE) is a frequent concomitant finding in malignant effusions but rarely the primary cause.
Thrombosis
Arteriosclerosis Thrombosis and Vascular Biology · 2014 · Q1 · SJR 2.00 · FWCI 21.84 · 1,150 citations · Open access
Venous thromboembolism (VTE) represents a significant global disease burden, causing more disability-adjusted life-years lost than common hospital-acquired infections and adverse drug events.
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism
Circulation · 2013 · Q1 · SJR 8.00 · FWCI 38.55 · 1,118 citations
Ultrasound-assisted catheter-directed thrombolysis (USAT) significantly reversed right ventricular dilation in intermediate-risk pulmonary embolism patients within 24 hours, outperforming heparin alone.
Pulmonary Embolism in Patients With COVID-19
Circulation · 2020 · Q1 · SJR 8.00 · FWCI 133.15 · 1,116 citations · Open access
Critically ill COVID-19 patients in the ICU experienced pulmonary embolism (PE) at a rate of 20.6%, which is double the rate observed in non-COVID-19 ICU patients during the same period.
The epidemiology of venous thromboembolism
Journal of Thrombosis and Thrombolysis · 2016 · Q2 · FWCI 67.79 · 1,089 citations · Open access
Venous thromboembolism (VTE) is a significant public health issue characterized by frequent recurrence, reduced survival, and high healthcare costs.
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 87.99 · 1,044 citations · Open access
Oral apixaban proved noninferior to subcutaneous dalteparin in treating cancer-associated venous thromboembolism, with a similar risk of major bleeding.
Recently added
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Blood Advances · 2021 · Q1 · SJR 3.00 · FWCI 118.50 · 854 citations · Open access
New American Society of Hematology (ASH) guidelines recommend against thromboprophylaxis for low-risk ambulatory cancer patients receiving chemotherapy, but strongly advise low-molecular-weight heparin (LMWH) for initial VTE treatment in cancer patients.
Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis
Radiology · 2020 · Q1 · SJR 4.00 · FWCI 18.57 · 501 citations
This systematic review and meta-analysis found that COVID-19 patients have a significantly higher incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-COVID-19 patients.
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
Annals of Internal Medicine · 2020 · Q1 · SJR 2.00 · FWCI 82.07 · 667 citations
Autopsies of COVID-19 patients revealed fatal pulmonary embolisms in one-third of cases, contradicting the notion that VTE is merely an epiphenomenon and highlighting the need for further research into anticoagulant therapy.
Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis
EClinicalMedicine · 2020 · Q1 · SJR 4.00 · FWCI 30.09 · 720 citations · Open access
COVID-19 patients have a 21% overall venous thromboembolism (TE) rate (31% in ICU) and a 2% arterial TE rate (5% in ICU), with TE associated with a 74% higher mortality risk (OR 1.74).
Venous thromboembolism in cancer patients: a population-based cohort study
Blood · 2020 · Q1 · SJR 5.00 · FWCI 37.08 · 707 citations · Open access
The 12-month incidence of venous thromboembolism (VTE) in cancer patients increased from 1.0% in 1997 to 3.4% in 2017, a nearly ninefold higher risk than the general population (2.3% vs. 0.35% in 2017).
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Blood Advances · 2020 · Q1 · SJR 3.00 · FWCI 85.40 · 1,434 citations · Open access
The American Society of Hematology (ASH) will continue to monitor evidence for its 2020 Venous Thromboembolism (VTE) management guidelines, opting against revision or retirement at this time.
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Research and Practice in Thrombosis and Haemostasis · 2020 · Q1 · SJR 1.00 · FWCI 20.86 · 503 citations
A meta-analysis of 86 studies (33,970 patients) found an overall venous thromboembolism (VTE) prevalence of 14.1% in COVID-19 patients, rising to 22.7% in ICU patients and 7.9% in non-ICU hospitalized patients.
Pulmonary Embolism in Patients With COVID-19
Circulation · 2020 · Q1 · SJR 8.00 · FWCI 133.15 · 1,116 citations · Open access
Critically ill COVID-19 patients in the ICU experienced pulmonary embolism (PE) at a rate of 20.6%, which is double the rate observed in non-COVID-19 ICU patients during the same period.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 15 | 376 |
| Blood Advances | Q1 | 3.00 | 110 | 5 | 7 |
| Circulation | Q1 | 8.00 | 712 | 4 | 46 |
| JAMA | Q1 | 5.00 | 818 | 4 | 114 |
| European Heart Journal | Q1 | 5.00 | 385 | 4 | 50 |
| Journal of Clinical Oncology | Q1 | 4.00 | 666 | 4 | 38 |
| Blood | Q1 | 5.00 | 556 | 3 | 21 |
| Radiology | Q1 | 4.00 | 357 | 2 | 14 |
Every journal in Internal Medicine (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app